BERLIN, Aug. 5 (Xinhua) — German pharmaceutical giant Bayer said Thursday its sales in the second quarter (Q2) of the year grew by 8 percent year-on-year to 10.85 billion euros (12.86 billion U.S. dollars).
Bayer also announced Thursday to acquire the U.S. biotech company Vividion Therapeutics, paying almost 1.27 billion euros, plus up to another 422 million euros based on the performance of the protein analysis specialist.
In Q2, Bayer achieved “major successes in developing and launching drugs, some of which have blockbuster potential,” said Werner Baumann, chairman of the board of management, adding that the recent acquisition further strengthened the company’s pharmaceutical research base.
Sales in the pharmaceuticals segment increased by 12.6 percent year-on-year and reached 4.5 billion euros in Q2, as the segment “showed a robust recovery from the COVID-19 restrictions,” Bayer said.
The company’s agricultural business reported growth in all regions, with sales growing by 10.6 percent to 5.0 billion euros in Q2.
Bayer expressed optimism for the rest of the year, expecting sales of 44 billion euros in 2021 instead of 42 to 43 billion euros. (1 euro = 1.19 U.S. dollars)
Originally Appeared Here